Table 1.
Baseline characteristics of patient sample.
|
Total Sample N = 109 |
|||
|---|---|---|---|
| Age (years) | 64.1 ± 11.7 | ||
| Female | 65 (60) | ||
| PCSK9 Inhibitor | |||
| Evolocumab 140mg | 62 (57) | ||
| Alirocumab 75mg | 23 (21) | ||
| Alirocumab 150 mg | 24 (22) | ||
| ASCVD | 98 (90) | ||
| Coronary | 87 | ||
| Peripheral | 2 | ||
| Cerebral | 1 | ||
| Polyvascular | 2 | ||
| Coronary calcium | 6 | ||
| FH without ASCVD | 11 (10) | ||
| Diabetes | 37 (34) | ||
| Lipid diagnosis ASCVD | |||
| Hypercholesterolemia alone | 61 (56) | ||
| Combined hyperlipidemia | 37 (34) | ||
| Therapy | Statin Intolerance | Any Statin | Any LLRx |
| ASCVD | 78 (80) | 20 (20) | 44 (45) |
| FH | 9 (82) | 2 (18) | 2 (18) |
ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LLRx, lipid lowering therapy; PCSK9, proprotein convertase subtilisin kexin 9.
Data presented as frequency (%) or mean ± SD.